In 2011, ten years after the last confirmed outbreak, the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (WOAH, formerly OIE) jointly declared global freedom from rinderpest. Rinderpest, also known as cattle plague, is only the second infectious disease eradicated from the world, smallpox being the first. Over the 10 years since eradication, the main goal of the Rinderpest Post-Eradication Programme (https://www.woah.org/en/disease/rinderpest) has been to track and reduce global stocks of rinderpest virus–containing material (RVCM).

RVCM comprises field and laboratory strains of rinderpest virus; vaccine strains of rinderpest virus, including valid and expired vaccine stocks; tissues, serum, and other clinical material from infected or suspect animals; diagnostic material containing or encoding live virus; recombinant morbilliviruses (segmented or nonsegmented) containing unique rinderpest virus nucleic acid or amino acid sequences; and full-length genomic material, including from virus RNA and cDNA copies of virus RNA. Subgenomic fragments of morbillivirus nucleic acid not capable of incorporation into a replicating morbillivirus or morbillivirus-like viruses are not considered RVCM.

Accounting for remaining RVCM is critical to limit the risk for reintroducing the pathogen by intentional or inadvertent release from a laboratory (1). In support of this effort, in 2015, FAO and WOAH started the Sequence and Destroy project, which enabled whole-genome sequencing of rinderpest virus (RPV) isolates before their destruction. Participating institutes were expected to deposit the genome sequences into publicly accessible databases. In addition, FAO has provided hands-on assistance and remote support to destroy viral stocks in Africa and Asia and led organization of >5 global and regional advocacy meetings. During June–October 2021, a review was conducted to mark progress towards RVCM sequestration and destruction 10 years after eradication. We report the main findings of this review.

The Study
In 2011, a total of 150 countries were surveyed regarding their RVCM stocks (2). At that time, 35 countries (44 laboratories) reported keeping RVCM. In 2013, WOAH began annual surveys of institutes keeping RVCM. In 2013, WOAH began annual surveys of institutes keeping RVCM. In 2013, a total of 23 countries reported keeping RVCM; 13 kept live virulent virus and 19 live-attenuated virus in the form of vaccine (n = 17) or seedstock (n = 17), and 9 countries kept both virulent virus and vaccine. Because FAO and WOAH worked with members to eliminate or transfer RVCM stocks, the number of countries keeping RVCM had decreased to 12 (14 institutes) as of 2021 (Figure). In addition, FAO/ WOAH designated some of these institutes either
category A or B or dual-category rinderpest-holding facilities (RHF) (https://www.oie.int/en/disease/rinderpest/#ui-id-3). Category A RHFs are designated for storing RVCM, excluding vaccine stocks; category B RHFs are approved for storing only manufactured vaccines and materials for their production.

To confirm that no relevant findings unknown to WOAH had been published by research groups or laboratories, we reviewed the scientific literature to identify any publications about rinderpest virus research undertaken since 2011. A search of 21 databases identified 623 unique publications of which we evaluated 17 at the full-text level (Appendix Table 1, https://wwwnc.cdc.gov/EID/article/28/9/22-0297-App1.pdf). The search identified no institutes conducting work with RVCM not already known to WOAH. Nine (53%) of 17 reviewed studies were conducted in facilities that are FAO/WOAH-designated RHFs; 4/17 were published in 2011. Besides genome sequencing data, the main finding from recent research was that vaccination of cattle with peste des petits ruminants virus (PPRV) does not provide protective immunity against RPV (3), leading to the decision to maintain and even expand global contingency stocks of RPV vaccine (Appendix Table 2).

Members of the study team contacted a representative from each institute known by WOAH to keep RVCM as of August 2021 to arrange an interview to discuss current and historic RVCM stocks and laboratory biosecurity. Interviews were conducted remotely and accompanied by completion of a structured questionnaire. All institutes keeping RVCM, except for 1 located in the Middle East, responded to the request for an interview. Because of logistical difficulties and COVID-19–related challenges, interviews were not conducted with institutes in 2 countries in Europe. Therefore, during August 8–September 17, 2021, interviews proceeded with 11 of the 14 institutes known to keep RVCM. Several of the institute directors contacted were not familiar with the specific content of their RVCM stocks and indicated that these materials were simply in

Figure. Number of institutes (A) and countries (B) keeping RVCM, by year, 2011 and 2013–2021. Data from 2011 are based on a single study, whereas data for 2013–2021 are based on WOAH country reports and institute director interviews (2021). FAO, Food and Agriculture Organization of the United Nations; RVCM, rinderpest virus–containing material; WOAH, World Organisation for Animal Health.
storage, which is concerning because of the critical nature of these materials. At present, Africa is the only region actively attempting to consolidate its RVCM into a single facility.

According to Resolution 18, passed in 2011 during the 79th general session of the World Assembly of WOAH Delegates: “Rinderpest virus-containing material that is not in an approved BSL3 [Biosecurity Level 3] facility shall be destroyed by a validated process or transferred to an approved BSL3 facility.” Biosafety levels for institutes keeping RVCM during 2011–2021 ranged from BSL2 to BSL4 (Table) meaning some institutes still do not meet this requirement; continued efforts are therefore needed. Three category B RHFs have actively contributed to the global rinderpest vaccine reserve. One institute in Europe keeps a rinderpest RBOK (Muguga-modification of the Kabate-0-strain) vaccine seed bank sufficient to produce ±800,000 doses. One institute in the WOAH Asia and the Pacific region biannually produces a total reserve of ±772,000 doses of LA-AKO (master seed virus) strain vaccine. One institute in Africa has a historic reserve of ±959,000 doses of RBOK vaccine. Three RHFs have participated in sequence and destroy projects, and 2 more have initiated the approval process for sequence and destroy projects from the FAO/WOAH rinderpest secretariat.

During recent genomic analysis of PPRV isolates held at an FAO/WOAH-designated RHF, 1 sample was found to contain a sequence that aligned with RPV in addition to PPRV sequences. A traceback investigation found that this sample, obtained from the field by another institute in the early 1970s, appears to have been destroyed. All materials derived from the original stock before the contaminated sample was identified were uncontaminated, but those derived from the contaminated stock were RPV-contaminated, so contamination appears to have occurred inside the institute, from an unknown source, but likely during a period in the late 1990s when both RPV and PPRV were being manipulated concurrently at the institute. All contaminated samples were destroyed. After examining all other samples being manipulated during the same period, the institute concluded that no others were contaminated. Records indicated that the institute had not shared this sample with other facilities and that it would thereafter screen all PPRV samples by PCR for RPV before sharing them. No contaminated samples had escaped containment and all processes to secure stocks appeared to be working well. Risks associated with remaining global stocks are being evaluated and will be presented in a future publication.

**Conclusions**

We document discovery of RPV-contaminated PPRV samples; our findings suggest that because of risk for cross-contamination, other laboratories should take precautions with samples manipulated alongside RPV, especially PPRV. Although progress is being made in consolidating RVCM stocks, 2 of 6 nonapproved institutes known to keep RVCM stockpiles have indicated no plans to destroy or transfer them to an FAO/WOAH RHF. Therefore, in spite of the progress, much work remains. Current FAO/WOAH strategy is to continue removing RVCM from nonapproved laboratories and advocating for reduced RVCM stocks in FAO/WOAH-designated RHFs. Ultimately, the only remaining RVCM materials should be manufactured vaccines and materials for vaccine production and diagnostics.

**Acknowledgments**

The authors thank the members of the Rinderpest Holding Facility Network and other laboratories interviewed during this process and recognize the contribution of the Food and Agriculture Organization of the United Nations. We thank Heather Moberly for assistance with the literature review and Sarah Manning for assistance creating the figures.

### Table. Regional institutes with rinderpest virus–containing material, by biosafety level and type, for 2013 and 2021*

| Category | Africa | Asia, Far East, and Oceania | Europe | Middle East | The Americas | World |
|----------|--------|-------------------------------|--------|-------------|--------------|-------|
| Biologic safety level |        |                               |        |             |               |       |
| 2        | 3/0    | 1/2                           | 0/0    | 1/1         | 1/0          | 6/3   |
| 2+       | 0/0    | 0/1                           | 0/0    | 0/0         | 0/0          | 0/1   |
| 3        | 4/1    | 9/3                           | 3/3    | 0/0         | 2/1          | 18/8  |
| 3+       | 0/0    | 0/0                           | 1/1    | 0/0         | 0/0          | 1/1   |
| 4        | 0/1    | 0/0                           | 2/0    | 0/0         | 0/0          | 2/1   |
| Unknown  | 1/0    | 0/0                           | 0/0    | 0/0         | 0/0          | 1/0   |
| Type     |        |                               |        |             |               |       |
| A        | 0/0    | 0/1                           | 0/1    | 0/0         | 0/1          | 0/3   |
| B        | 0/0    | 0/1                           | 0/0    | 0/0         | 0/0          | 0/1   |
| A/B      | 0/1    | 0/1                           | 0/1    | 0/0         | 0/0          | 0/3   |
| Unofficial | 8/1   | 10/3                          | 6/2    | 1/1         | 3/0          | 28/7  |
| Overall  | 8/2    | 10/6                          | 6/4    | 1/1         | 3/1          | 28/14 |

*Values are given as 2013/2021 numbers.
The project or effort depicted was or is sponsored by the United States Department of Defense, Defense Threat Reduction Agency. The content of the information does not necessarily reflect the position or the policy of the Federal Government of the United States, and no official endorsement should be inferred.

About the Author
Dr. Budke is a professor of epidemiology at Texas A&M University and a senior lead scientist in risk prevention for the Institute for Infectious Animal Diseases (IIAD). Her research interests include epidemiology, burden of disease indicators, zoonotic diseases, and international veterinary medicine and public health.

References
1. Fournié G, Jones BA, Beauvais W, Lubroth J, Njeumi F, Cameron A, et al. The risk of rinderpest re-introduction in post-eradication era. Prev Vet Med. 2014;113:175–84. https://doi.org/10.1016/j.prevetmed.2013.11.001
2. Fournié G, Beauvais W, Jones BA, Lubroth J, Ambrosini F, Njeumi F, et al. Rinderpest virus sequestration and use in post-eradication era. Emerg Infect Dis. 2013;19:151–3. https://doi.org/10.3201/eid1901.120967
3. Holzer B, Hodgson S, Logan N, Willett B, Baron MD. Protection of cattle against rinderpest by vaccination with wild-type but not attenuated strains of peste des petits ruminants virus. J Virol. 2016;90:5152–62. https://doi.org/10.1128/JVI.00040-16

Address for correspondence: Christine M. Budke, Texas A&M University, 4458 TAMU, College Station, TX 77843-4458, USA; email: CBudke@cvm.tamu.edu

Antimicrobial Resistance

To revisit the January 2022 issue, go to:
https://wwwnc.cdc.gov/eid/articles/issue/28/1/table-of-contents
# Sequestration and Destruction of Rinderpest Virus–Containing Material 10 Years after Eradication

## Appendix

**Appendix Table 1.** Search terms used in the literature review to identify publications related to rinderpest virus research undertaken since 2011, among 21 databases searched

| Search terms | Results |
|--------------|---------|
| Global Health 1910–2021 week 26 exp Rinderpest morbillivirus/ or exp rinderpest/ or rinderpest*.ti,ab Limited to 2011–2022 | 432 81 |
| EMBASE OVID interface 1974–2021 June 30 exp Rinderpest virus/ or exp rinderpest/ or exp Cattle plague virus/ or rinderpest*.ti,ab Limited to 2011–2022 | 829 192 |
| CAB Abstracts OVID interface 1910–2021 Week 26 exp Rinderpest morbillivirus/ or exp rinderpest/ or rinderpest*.ti,ab. Limited to 2011–2022 | 4,340 274 |
| International Pharmaceutical Abstracts OVID interface 1970-June 2021 Rinderpest*.ti,ab. | 1 |
| JBI EBP OVID interface current to June 23, 2021 Rinderpest*.ti,ab. | 1 |
| Northern Light Life Sciences Conference Abstracts OVID interface 2010–2021 Week 25 Rinderpest*.ti,ab. Limited to 2011–2022 | 6 5 |
| MEDLINE OVID interface OVID interface exp Rinderpest virus/ or exp Rinderpest/ or rinderpest*.ti,ab. Limited to 2011–2022 | 1,186 162 |
| CINAHL Complete EBSCOhost interface rinderpest* in Title OR rinderpest* in Abstract OR rinderpest* as a word in subject heading Limited to 01/01/2011–12/31/2021 | 14 7 |

Web of Science Collection Databases searched simultaneously via Web of Science interface
- Science Citation Index- 1900-present
- Social Science Citation Index 1900-present
- Arts & Humanities Citation Index 1975-present
- Conference Proceedings Citation Index-Science 1990-present
- Conference Proceedings Citation Index-Social Science & Humanities 1990-present
- Book Citation Index-Science 2005-present
- Book Citation Index-Social Science & Humanities 2005-present
- Emerging Sources Citation Index 2005-present
- Current Chemical Reactions 1985-present
- Index Chemicus 1993-present

TI = (rinderpest*) OR AB = (rinderpest*) OR TS = (rinderpest)
**Appendix Table 2.** Summary of studies involving rinderpest virus published between 2011 and 2021.

| Study category          | Summary                                                                                                                                   | Lab location                  | Reference |
|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|-----------|
| **Vaccine development/Immunity** | The crystal structure of MHC 1 N*01801 complexed to rinderpest derived peptide IPA was evaluated and analysis revealed that the MHC groove can assume different conformations to bind with the rinderpest viral peptide. RPV was cultured by utilizing a vaccine strain of the virus and it was mutated based on potential C1 monoclonal antibody binding sites. After characterizing C1 binding sites, it was discovered that the deletion or mutation of these sites resulted in C1 not being able to bind to RPV. Cattle were vaccinated with either wild-type or two established PPRV vaccine strains to determine the degree of protection to which individuals vaccinated for PPR have against RPV. Only animals vaccinated with the wild-type PPRV were protected from RPV challenge. These individuals were also able to neutralize RPV-pseudotyped vesicular stomatitis virus. | Beijing, China                | 1         |
| **Diagnostics**         | The goal of this study was to develop a one-step multiplex reverse transcription PCR assay for the simultaneous detection of Rift Valley Fever Virus, Bluetongue Virus, RPV, and PPRV. Dual-Priming Oligonucleotide was used to develop the diagnostic test for the four viruses. | Anyang, Republic of Korea     | 4         |
|                         | This study used a replication-defective vesicular stomatitis virus based pseudotyping system to measure neutralizing antibodies against RPV and PPR. This system does not require the use of live infectious viral materials and thus mitigates the risk of accidental exposure. Analysis revealed that individuals vaccinated for RPV also are protected against PPR infection. Individuals that were vaccinated against PPR had lower antibody titers than those who were naturally infected and in individuals infected with either PPR or RPV neutralizing responses were highest against the homologous virus. This indicates that retrospective analysis of serologic samples can be used to determine the pathogen to which an infected individual was exposed. | Pirbright, United Kingdom*    | 5         |
|                         | This study focuses on the development of a multiplex RT-PCR and automated microarray assay for the simultaneous detection of eight important cattle viruses: vesicular stomatitis virus, bluetongue virus, bovine viral diarrhea virus type 1 and 2, malignant catarrhal fever virus, bovine herpesvirus-1, parapox virus complex, and RPV. Because of the request to destroy all RPV samples following eradication a new diagnostic method must be developed that does not rely on RPV as a positive material. Newcastle Disease with small RNA inserts based on RPV or PPV was used as a positive control for extraction, reverse transcription, and amplification. | Lelystad, Netherlands†        | 7         |
| **Enzyme activity**     | The V proteins of RPV, measles virus, PPR, and canine distemper were compared to determine which had the ability to block type 1 and type 2 interferon action. Analysis revealed that the V proteins of each morbillivirus could block type 1 interferon action but they had varying abilities to block type 2 interferon action which is correlated with the co-precipitation of STAT1 with the V protein. Further analysis revealed that all morbillivirus V proteins form a complex with Tyk2 and Jak2, two interferon-receptor-associated kinases. The enzymatic role of RPV V protein was investigated to determine how it blocks interferon signaling. Analysis revealed that the morbillivirus V proteins have at least three functions that inhibit interferon signaling, the binding of STAT1 also seen with P and W proteins) which enables the blockade of type 2 interferon signaling, the binding of STAT1 which requires the Vs domain and | Pirbright, UK*                | 8         |
|                         |                                                                                                                                           |                               |           |
part of the W domain, and the association with interferon receptor-associated kinases which also requires the Vs domain.

**Study category:**

**Summary:**

 Partially purified recombinant RNA polymerase complex of RPV was used to show in vitro methylation of capped mRNA. Analysis revealed that the catalytic module for cap 0 methyl transferase activity is located in domain 3 of the L protein whereas domain 2 stabilizes the enzyme and increases catalytic efficiency. This provides support for the modular nature of the RPV L protein.  

**E. coli** was used to express the RTPase domain of RPV to investigate the RTPase activity of L protein. Analysis revealed that L protein exhibits RTPase and NTPase activities and that it has a two-metal mechanism similar to the RTPase domain of other viruses.  

**E. coli** was used to express the RTPase domain of RPV to investigate its enzymatic abilities. Analysis revealed that the L protein of RPV has RNA-dependent RNA polymerase, RTPase, Guanylyltransferase (GTase), and Methyltransferase activity in addition to pyrophosphatase (Ppase) and triplypolphosphatase (PPPase) activity.

**Genome sequencing:**

The B and L strains of RPV were sequenced to investigate host range and virulence factors. The stock B strain is pathogenic to cattle whereas the L strain is pathogenic to rabbits but not cattle and buffalo. Analysis revealed that differences in pathogenicity to cattle is caused by m/aa substitution in P/C/V genes.  

The LATC06 strain of RPV was sequenced and compared to other rinderpest viral strains. Analysis revealed that the functions of the LATC06 (Korea) and LA (Japan) strains of RPV are similar with regards to immunodominance in humoral immunity.  

The genomes of three strains of RPV, L72, LA77, and LA96, were sequenced and analyzed to investigate their genetic variability. Analysis revealed that genetic variability occurs within the vaccine virus strain and that amino acid sequence similarity between Fusan and other strains was the lowest within the P, C, and V proteins. This indicated that the difference in pathogenicity of different strains may be Because of the V protein.  

The LA-AKO strain of the RPV vaccine was sequenced. Analysis revealed that the bulk vaccine comprises mixed viral populations with minor mutations at the nucleotide level.  

In preparation for the destruction of all RPV samples, the full genome sequence was determined of each distinct RPV sample housed at Pirbright. Analysis revealed that the African isolates form a single disparate clade as opposed to two separate clades and that the clade containing viruses developed in Korea were more similar to African viruses than Asian viruses.

**Lab location**

Bangalore, India§

Bangalore, India§

Bangalore, India§

Tokyo, Japan*

Anyang, Korea

Anyang, Korea

Ibaraki, Japan*,‡

Pirbright, United Kingdom*,‡

**Reference**

1. Li X, Liu J, Qi J, Gao F, Li Q, Li X, et al. Two distinct conformations of a rinderpest virus epitope presented by bovine major histocompatibility complex class I N*01801: a host strategy to present featured peptides. J Virol. 2011;85:6038–48. PubMed https://doi.org/10.1128/JVI.00030-11

2. Buczkowski H, Parida S, Bailey D, Barrett T, Banyard AC. A novel approach to generating morbillivirus vaccines: negatively marking the rinderpest vaccine. Vaccine. 2012;30:1927–35. PubMed https://doi.org/10.1016/j.vaccine.2012.01.029

3. Holzer B, Hodgson S, Logan N, Willett B, Baron MD. Protection of cattle against rinderpest by vaccination with wild-type but not attenuated strains of peste des petits ruminants virus. J Virol. 2016;90:5152–62. PubMed https://doi.org/10.1128/JVI.00040-16
4. Yeh JY, Lee JH, Seo HJ, Park JY, Moon JS, Cho IS, et al. Simultaneous detection of Rift Valley fever, bluetongue, rinderpest, and peste des petits ruminants viruses by a single-tube multiplex reverse transcriptase-PCR assay using a dual-priming oligonucleotide system. J Clin Microbial. 2011;49:1389–94.

5. Logan N, Dundon WG, Diallo A, Baron MD, James Nyarobi M, Cleaveland S, et al. Enhanced immunosurveillance for animal morbilliviruses using vesicular stomatitis virus (VSV) pseudotypes. Vaccine. 2016;34:5736–43. PubMed https://doi.org/10.1016/j.vaccine.2016.10.010

6. Lung O, Furukawa-Stoffer T, Burton Hughes K, Pasick J, King DP, Hodko D. Multiplex RT-PCR and automated microarray for detection of eight bovine viruses. Transbound Emerg Dis. 2017;64:1929–34. PubMed https://doi.org/10.1111/tbed.12591

7. van Rijn PA, Boonstra J, van Gennip HGP. Recombinant Newcastle disease viruses with targets for PCR diagnostics for rinderpest and peste des petits ruminants. J Virol Methods. 2018;259:50–3. PubMed https://doi.org/10.1016/j.jviromet.2018.06.007

8. Chinnakannan SK, Nanda SK, Baron MD. Morbillivirus V proteins exhibit multiple mechanisms to block type 1 and type 2 interferon signalling pathways. PLoS One. 2013;8:e57063. PubMed https://doi.org/10.1371/journal.pone.0057063

9. Chinnakannan SK, Holzer B, Bernardo BS, Nanda SK, Baron MD. Different functions of the common P/V/W and V-specific domains of rinderpest virus V protein in blocking IFN signalling. J Gen Virol. 2014;95:44–51. PubMed https://doi.org/10.1099/vir.0.056739-0

10. Gopinath M, Shaila MS. Evidence for N⁷ guanine methyl transferase activity encoded within the modular domain of RNA-dependent RNA polymerase L of a morbillivirus. Virus Genes. 2015;51:356–60. PubMed https://doi.org/10.1007/s11262-015-1252-3

11. Singh PK, Ratnam N, Narayanarao KB, Bugatha H, Karande AA, Melkote Subbarao S. A carboxy terminal domain of the L protein of rinderpest virus possesses RNA triphosphatase activity—the first enzyme in the viral mRNA capping pathway. Biochem Biophys Res Commun. 2015;464:629–34. PubMed https://doi.org/10.1016/j.bbrc.2015.07.026

12. Singh PK, Subbarao SM. The RNA triphosphatase domain of L protein of rinderpest virus exhibits pyrophosphatase and tripolyphosphatase activities. Virus Genes. 2016;52:743–7. PubMed https://doi.org/10.1007/s11262-016-1353-7
13. Fukai K, Morioka K, Sakamoto K, Yoshida K. Characterization of the complete genomic sequence of the rinderpest virus Fusan strain cattle type, which is the most classical isolate in Asia and comparison with its lapinized strain. Virus Genes. 2011;43:249–53. PubMed https://doi.org/10.1007/s11262-011-0630-8

14. Yeh JY, Kwoen CH, Jeong W, Jeoung HY, Lee HS, An DJ. Genetic characterization of the Korean LATC06 rinderpest vaccine strain. Virus Genes. 2011;42:71–5. PubMed https://doi.org/10.1007/s11262-010-0543-y

15. Jeoung HY, Lee MH, Yeh JY, Lim JA, Lim SI, Oem JK, et al. Complete genome analysis of three live attenuated rinderpest virus vaccine strains derived through serial passages in different culture systems. J Virol. 2012;86:13115–6. PubMed https://doi.org/10.1128/JVI.02362-12

16. Takamatsu H, Terui K, Kokuho T. Complete genome sequence of Japanese vaccine strain LA-AKO of rinderpest virus. Genome Announc. 2015;3:e00976–15. PubMed https://doi.org/10.1128/genomeA.00976-15

17. King S, Rajko-Nenow P, Ropiak HM, Ribeca P, Batten C, Baron MD. Full genome sequencing of archived wild type and vaccine rinderpest virus isolates prior to their destruction. Sci Rep. 2020;10:6563. PubMed https://doi.org/10.1038/s41598-020-63707-z